경구 비만 치료제 시장 보고서(2026년)

Oral obesity therapies refer to orally administered medications designed to help manage and treat obesity by affecting appetite, metabolism, or fat absorption. These therapies function through different mechanisms, including suppressing hunger signals in the brain, enhancing feelings of fullness, or decreasing the absorption of dietary fat within the digestive system.

The primary drug classes of oral obesity therapies include lipase inhibitors, sympathomimetic appetite suppressants, combination therapies, oral glp-1 agonists, and other oral mechanisms. Lipase inhibitors refer to medications that reduce fat absorption in the digestive system to support weight reduction and obesity management. The different patient indications include bmi >=30 primary obesity, overweight + metabolic comorbidities, short-term weight reduction, weight maintenance, and adolescent populations, and the different sales channels include retail pharmacies, mail-order pharmacies, telehealth platforms, hospital outpatient pharmacies, and specialty pharmacies. The various applications involved include obesity management, weight loss maintenance, cardiometabolic risk reduction, and pre-surgical weight control, and they are utilized by end users including hospitals, clinics, and homecare settings.

Tariffs are affecting the oral obesity therapies market by increasing the cost of imported active pharmaceutical ingredients, advanced formulation technologies, and specialty excipients used in oral drug manufacturing. This is disrupting global supply chains and increasing production expenses, particularly in regions reliant on pharmaceutical imports such as Asia-Pacific and Latin America. Segments such as oral GLP-1 agonists, combination therapies, and lipase inhibitors are most impacted due to complex manufacturing dependencies and cross-border sourcing of biologics and intermediates. However, tariffs are also encouraging regional API manufacturing, expansion of domestic pharmaceutical production, and strategic supply chain diversification, which may improve long-term resilience and reduce reliance on concentrated global suppliers.

The oral obesity therapies market research report is one of a series of new reports from The Business Research Company that provides oral obesity therapies market statistics, including oral obesity therapies industry global market size, regional shares, competitors with a oral obesity therapies market share, detailed oral obesity therapies market segments, market trends and opportunities, and any further data you may need to thrive in the oral obesity therapies industry. This oral obesity therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral obesity therapies market size has grown strongly in recent years. It will grow from $3.94 billion in 2025 to $4.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing global obesity prevalence, rising awareness of metabolic health risks, expansion of prescription-based weight management drugs, growth in clinical research on appetite regulation mechanisms, increasing healthcare focus on non-invasive obesity treatments.

The oral obesity therapies market size is expected to see strong growth in the next few years. It will grow to $6.32 billion by 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to rising adoption of oral glp-1 therapies, increasing demand for personalized metabolic treatments, growth in telemedicine-based obesity care, expansion of next-generation oral incretin drugs, rising investment in obesity drug pipelines by pharma companies. Major trends in the forecast period include rising adoption of oral glp-1 based therapies for appetite regulation and weight management, increasing use of combination oral obesity drugs targeting multiple metabolic pathways, growing demand for personalized obesity treatment based on genetic and metabolic profiling, expansion of telehealth enabled prescription access for oral weight loss therapies, rising development of gut hormone modulating oral drugs for improved metabolic control.

The increasing prevalence of obesity is expected to drive the growth of the oral obesity therapies market going forward. Obesity refers to a medical condition characterized by excessive accumulation of body fat that elevates the risk of health conditions such as heart disease, diabetes, and hypertension. Obesity is increasing mainly due to greater consumption of calorie-dense processed foods, which results in excess energy intake and gradual weight gain when not balanced with physical activity. Oral obesity therapies help manage obesity by regulating hunger-related hormones and reducing calorie absorption, contributing to sustained weight management and improved health outcomes. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, during 2023-2024, the prevalence of overweight conditions, including obesity, among adults was higher in men (69.7%) than in women (59.2%), while obesity alone was slightly more common in women (26.9%) compared to men (26.2%). Therefore, the increasing prevalence of obesity is driving the growth of the oral obesity therapies market.

Leading companies operating in the oral obesity therapies market are focusing on developing innovative solutions such as incretin-based therapy to improve weight loss efficacy, enhance metabolic outcomes, and provide convenient non-injectable treatment options for patients. Incretin-based therapy refers to a class of treatments that mimic or enhance the action of incretin hormones, such as GLP-1, to regulate blood sugar levels, suppress appetite, and support weight loss. For instance, in January 2026, Novo Nordisk, a Denmark-based healthcare company, launched an LP-1 pill for obesity called the Wegovy pill (oral semaglutide) for chronic weight management in adults with obesity or overweight alongside related conditions, in combination with diet and exercise. It was also approved to reduce cardiovascular risks such as heart attacks and strokes in individuals with established heart disease.

In December 2023, Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche aims to strengthen its position in the obesity and metabolic disease segment by expanding its portfolio of incretin-based therapies, including oral GLP-1 drug candidates, and improving its drug development capabilities. Carmot Therapeutics Inc. is a US-based biotechnology company that provides oral obesity therapies.

Major companies operating in the oral obesity therapies market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Sun Pharmaceutical Industries Ltd., Jiangsu Hengrui Medicine Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Innovent Biologics Inc., Viking Therapeutics Inc., Rhythm Pharmaceuticals Inc., Septerna Therapeutics, Eccogene Inc., Currax Pharmaceuticals LLC, Ascletis Pharma Inc., Structure Therapeutics

North America was the largest region in the oral obesity therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral obesity therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oral obesity therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral obesity therapies market consists of sales of prescription oral anti-obesity drugs, over-the-counter weight management tablets, appetite suppressants, fat absorption inhibitors, and metabolic enhancers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Obesity Therapies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oral obesity therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral obesity therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral obesity therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Lipase Inhibitors; Sympathomimetic Appetite Suppressants; Combination Therapies; Oral GLP-1 Agonists; Other Oral Mechanisms
• 2) By Patient Indication: BMI >=30 Primary Obesity; Overweight + Metabolic Comorbidities; Short-term Weight Reduction; Weight Maintenance; Adolescent Populations
• 3) By Sales Channel: Retail Pharmacies; Mail-order Pharmacies; Telehealth Platforms; Hospital Outpatient Pharmacies; Specialty Pharmacies
• 4) By Application: Obesity Management; Weight Loss Maintenance; Cardiometabolic Risk Reduction; Pre-Surgical Weight Control
• 5) By End User: Hospitals; Clinics; Homecare Settings
• Subsegments:
• 1) By Lipase Inhibitors: Prescription Lipase Inhibitors; Over The Counter Lipase Inhibitors; High Dose Lipase Inhibitors; Low Dose Lipase Inhibitors; Generic Lipase Inhibitors; Branded Lipase Inhibitors
• 2) By Sympathomimetic Appetite Suppressants: Short Acting Appetite Suppressants; Long Acting Appetite Suppressants; Central Nervous System Stimulants; Adrenergic Appetite Suppressants; Prescription Appetite Suppressants; Extended Release Appetite Suppressants
• 3) By Combination Therapies: Appetite Suppressant And Antidepressant Combinations; Appetite Suppressant And Anticonvulsant Combinations; Multi Mechanism Combination Therapies; Fixed Dose Combination Therapies; Dual Mechanism Combination Therapies; Triple Mechanism Combination Therapies
• 4) By Oral Glucagon Like Peptide One Agonists: Daily Oral Glucagon Like Peptide One Agonists; Weekly Oral Glucagon Like Peptide One Agonists; High Potency Glucagon Like Peptide One Agonists; Sustained Release Glucagon Like Peptide One Agonists; Next Generation Incretin Agonists
• 5) By Other Oral Mechanisms: Serotonin Receptor Modulators; Metabolic Enhancers; Thermogenic Agents; Gut Hormone Modulators; Energy Expenditure Regulators; Dual Incretin Agonists
• Companies Mentioned: F. Hoffmann-La Roche AG; Merck & Co. Inc.; Pfizer Inc.; AstraZeneca PLC; Eli Lilly and Company; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; Boehringer Ingelheim GmbH; Sun Pharmaceutical Industries Ltd.; Jiangsu Hengrui Medicine Co. Ltd.; Celltrion Inc.; Zydus Lifesciences Limited; Jiangsu Hansoh Pharmaceutical Group Co. Ltd.; Hanmi Pharmaceutical Co. Ltd.; Innovent Biologics Inc.; Viking Therapeutics Inc.; Rhythm Pharmaceuticals Inc.; Septerna Therapeutics; Eccogene Inc.; Currax Pharmaceuticals LLC; Ascletis Pharma Inc.; Structure Therapeutics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Oral Obesity Therapies Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Oral Obesity Therapies Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Oral Obesity Therapies Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Oral Obesity Therapies Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Oral GLP-1 Based Therapies For Appetite Regulation And Weight Management
  • 4.2.2 Increasing Use Of Combination Oral Obesity Drugs Targeting Multiple Metabolic Pathways
  • 4.2.3 Growing Demand For Personalized Obesity Treatment Based On Genetic And Metabolic Profiling
  • 4.2.4 Expansion Of Telehealth Enabled Prescription Access For Oral Weight Loss Therapies
  • 4.2.5 Rising Development Of Gut Hormone Modulating Oral Drugs For Improved Metabolic Control

5. Oral Obesity Therapies Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Homecare Settings
• 5.4 Specialty Weight Management Centers
• 5.5 Other End Users

6. Oral Obesity Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oral Obesity Therapies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Oral Obesity Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Oral Obesity Therapies Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Oral Obesity Therapies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Oral Obesity Therapies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oral Obesity Therapies Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oral Obesity Therapies Market Segmentation

• 9.1. Global Oral Obesity Therapies Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lipase Inhibitors, Sympathomimetic Appetite Suppressants, Combination Therapies, Oral GLP-1 Agonists, Other Oral Mechanisms
• 9.2. Global Oral Obesity Therapies Market, Segmentation By Patient Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• BMI >=30 Primary Obesity, Overweight + Metabolic Comorbidities, Short-term Weight Reduction, Weight Maintenance, Adolescent Populations
• 9.3. Global Oral Obesity Therapies Market, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Retail Pharmacies, Mail-order Pharmacies, Telehealth Platforms, Hospital Outpatient Pharmacies, Specialty Pharmacies
• 9.4. Global Oral Obesity Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Obesity Management, Weight Loss Maintenance, Cardiometabolic Risk Reduction, Pre-Surgical Weight Control
• 9.5. Global Oral Obesity Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Homecare Settings
• 9.6. Global Oral Obesity Therapies Market, Sub-Segmentation Of Lipase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prescription Lipase Inhibitors, Over The Counter Lipase Inhibitors, High Dose Lipase Inhibitors, Low Dose Lipase Inhibitors, Generic Lipase Inhibitors, Branded Lipase Inhibitors
• 9.7. Global Oral Obesity Therapies Market, Sub-Segmentation Of Sympathomimetic Appetite Suppressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Short Acting Appetite Suppressants, Long Acting Appetite Suppressants, Central Nervous System Stimulants, Adrenergic Appetite Suppressants, Prescription Appetite Suppressants, Extended Release Appetite Suppressants
• 9.8. Global Oral Obesity Therapies Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Appetite Suppressant And Antidepressant Combinations, Appetite Suppressant And Anticonvulsant Combinations, Multi Mechanism Combination Therapies, Fixed Dose Combination Therapies, Dual Mechanism Combination Therapies, Triple Mechanism Combination Therapies
• 9.9. Global Oral Obesity Therapies Market, Sub-Segmentation Of Oral Glucagon Like Peptide One Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Daily Oral Glucagon Like Peptide One Agonists, Weekly Oral Glucagon Like Peptide One Agonists, High Potency Glucagon Like Peptide One Agonists, Sustained Release Glucagon Like Peptide One Agonists, Next Generation Incretin Agonists
• 9.10. Global Oral Obesity Therapies Market, Sub-Segmentation Of Other Oral Mechanisms, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Serotonin Receptor Modulators, Metabolic Enhancers, Thermogenic Agents, Gut Hormone Modulators, Energy Expenditure Regulators, Dual Incretin Agonists

10. Oral Obesity Therapies Market Regional And Country Analysis

• 10.1. Global Oral Obesity Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Oral Obesity Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oral Obesity Therapies Market

• 11.1. Asia-Pacific Oral Obesity Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oral Obesity Therapies Market

• 12.1. China Oral Obesity Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oral Obesity Therapies Market

• 13.1. India Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oral Obesity Therapies Market

• 14.1. Japan Oral Obesity Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oral Obesity Therapies Market

• 15.1. Australia Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oral Obesity Therapies Market

• 16.1. Indonesia Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oral Obesity Therapies Market

• 17.1. South Korea Oral Obesity Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oral Obesity Therapies Market

• 18.1. Taiwan Oral Obesity Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oral Obesity Therapies Market

• 19.1. South East Asia Oral Obesity Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oral Obesity Therapies Market

• 20.1. Western Europe Oral Obesity Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oral Obesity Therapies Market

• 21.1. UK Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oral Obesity Therapies Market

• 22.1. Germany Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oral Obesity Therapies Market

• 23.1. France Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oral Obesity Therapies Market

• 24.1. Italy Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oral Obesity Therapies Market

• 25.1. Spain Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oral Obesity Therapies Market

• 26.1. Eastern Europe Oral Obesity Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oral Obesity Therapies Market

• 27.1. Russia Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oral Obesity Therapies Market

• 28.1. North America Oral Obesity Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oral Obesity Therapies Market

• 29.1. USA Oral Obesity Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oral Obesity Therapies Market

• 30.1. Canada Oral Obesity Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oral Obesity Therapies Market

• 31.1. South America Oral Obesity Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oral Obesity Therapies Market

• 32.1. Brazil Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oral Obesity Therapies Market

• 33.1. Middle East Oral Obesity Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oral Obesity Therapies Market

• 34.1. Africa Oral Obesity Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Oral Obesity Therapies Market, Segmentation By Drug Class, Segmentation By Patient Indication, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oral Obesity Therapies Market Regulatory and Investment Landscape

36. Oral Obesity Therapies Market Competitive Landscape And Company Profiles

• 36.1. Oral Obesity Therapies Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Oral Obesity Therapies Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Oral Obesity Therapies Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

37. Oral Obesity Therapies Market Other Major And Innovative Companies

• Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Sun Pharmaceutical Industries Ltd., Jiangsu Hengrui Medicine Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Innovent Biologics Inc., Viking Therapeutics Inc., Rhythm Pharmaceuticals Inc., Septerna Therapeutics, Eccogene Inc., Currax Pharmaceuticals LLC

38. Global Oral Obesity Therapies Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Oral Obesity Therapies Market

41. Oral Obesity Therapies Market High Potential Countries, Segments and Strategies

• 41.1 Oral Obesity Therapies Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Oral Obesity Therapies Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Oral Obesity Therapies Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer